1,142
Views
24
CrossRef citations to date
0
Altmetric
Research Article

Synthesis and characterization of novel dioxoacridine sulfonamide derivatives as new carbonic anhydrase inhibitors

, , , &
Pages 509-514 | Received 05 May 2011, Accepted 14 Jun 2011, Published online: 16 Aug 2011
 

Abstract

Novel dioxoacridine sulfonamide compounds were synthesized from reaction of cyclic 1,3-diketones, sulfanilamide (4-amino benzene sulfonamide) and aromatic aldehydes. The structures of these compounds were confirmed by using spectral analysis (IR, H-NMR, 13C-NMR, and mass). Human carbonic anhydrase isoenzymes (hCA I and hCA II) were purified from erythrocyte cells by affinity chromatography. The inhibitory effects of sulfanilamide, acetazolamide (AAZ), and newly synthesized sulfonamides on hydratase and esterase activities of these isoenzymes have been studied in vitro. The IC50 values of compounds for esterase activity are 0.71–0.11 µM for hCA I and 0.45–0.12 µM for hCA II, respectively. The Ki values of these inhibitors were determined as 0,38–0,008 µM for hCA I and 0,19–0,001 µM for hCA II, respectively.

Acknowledgments

The authors are grateful to Prof. Dr. Yılmaz Yıldırır, Gazi University, Ankara, Turkey.

Declaration of interest

The authors are very grateful to Dumlupinar University Research Fund for providing financial support for this project (Grant No. 2008-4).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.